Leukemia Research
Volume 27, Issue 1 , Pages 79-84 , January 2003

The diphtheria toxin/urokinase fusion protein (DTAT) is selectively toxic to CD87 expressing leukemic cells

  • Jason G Ramage

      Affiliations

    • Department of Cancer Biology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA
    • ,
  • Daniel A Vallera

      Affiliations

    • Department of Therapeutic Radiology and Radiation Oncology, University of Minnesota Cancer Center, Minneapolis, MN, USA
    • ,
  • Jennifer H Black

      Affiliations

    • Department of Cancer Biology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA
    • ,
  • Peter D Aplan

      Affiliations

    • Department of Genetics, National Cancer Institute, Bethesda, MD, USA
    • ,
  • Ursula R Kees

      Affiliations

    • Telethon Institute for Child Health Research, Center for Child Health Research, University of Western Australia, Perth, Australia
    • ,
  • Arthur E Frankel

      Affiliations

    • Department of Cancer Biology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-336-716-3313; fax: +1-336-716-0255.

Received 4 March 2002 ,Accepted 22 April 2002.

References 

  1. Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman PP, et al.  Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood. 2001;98:548
  2. Estey EH. How I treat older patients with AML. Blood. 2000;96:1670
  3. Feuring-Buske M, Frankel AE, Gerhard B, Hogge D. Variable cytotoxicity of diphtheria toxin 388-granulocyte-macrophage colony-stimulating factor fusion protein for acute myelogenous leukemia stem cells. Exp Hematol. 2000;28:1390
  4. Alexander RL, Ramage J, Kucera GL, Caligiuri MA, Frankel AE. High affinity interleukin-3 receptor expression on blasts from patients with acute myelogenous leukemia correlates with cytotoxicity of a diphtheria toxin/IL-3 fusion protein. Leuk Res. 2001;25:875
  5. Ploug M, Ellis V. Structure-function relationships in the receptor for urokinase-type plasminogen activator. FEBS Lett. 1994;349:163
  6. Fazioli F, Blasi F. Urokinase-type plasminogen activator and its receptor: new targets for anti-metastatic therapy?. Trends Pharmcol Sci. 1994;15:25
  7. Preissner KT, Kanse SM, May AE. Urokinase receptor: a molecular organizer in cellular communication. Curr Opin Cell Biol. 2000;12:621
  8. Jardi M, Ingles-Esteve J, Burgal M, Azqueta C, Velasco F, Lopez-Pedrera C, et al. Distinct patterns of urokinase receptor (uPAR) expression by leukemic cells and peripheral blood cells. Thrombosis Haemostasis. 1996;76:1009
  9. Nykjaer A, Moller B, Todd RF, Christensen T, Andreasen PA, Gliemann J, et al. Urokinase receptor: an activation antigen in human T lymphocytes. J Immunol. 1994;152:505
  10. Lanza F, Castoldi GL, Castagnari B, Todd RF, Moretti S, Spisani S, et al.  Expression and functional role of urokinase-type plasminogen activator receptor in normal and acute leukaemic cells. Br J Haematol. 1998;103:110
  11. Sillaber C, Baghestanian M, Hofbauer R, Virgolini I, Bankl HC, Fureder W, et al.  Molecular and functional characterization of the urokinase receptor on human mast cells. J Biol Chem. 1997;272:7824
  12. Miles LA, Plow EF. Receptor mediated binding of the fibrinolytic components, plasminogen and urokinase, to peripheral blood cells. Thrombosis Haemostasis. 1987;58:936
  13. Plesner T, Ralfklaer E, Wittrup M, Johnsen H, Pyke C, Pedersen TL, et al.  Expression of the receptor for urokinase-type plasminogen activator in normal and neoplastic blood cells and hematopoietic tissue. Am J Clin Pathol. 1994;102:835
  14. Kroon ME, Koolwijk P, van der Vecht B, van Hinsbergh VWM. Urokinase receptor expression on human microvascular endothelial cells is increased by hypoxia: implications for capillary-like tube formation in a fibrin matrix. Blood. 2000;96:2775
  15. Haddock RC, Spell ML, Baker CD, Grammer R, Parks JM, Speidel M, et al.  Urokinase binding and receptor identification in cultured endothelial cells. J Biol Chem. 1991;266:21466
  16. Plow EF, Freaney DE, Plescia J, Miles LA. The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type. J Cell Biol. 1986;103:2411
  17. Blasi F, Stoppelli MP, Cubellis MV. The receptor for urokinase-plasminogen activator. J Cell Biochem. 1986;32:179
  18. Ragno P, Montuori N, Covelli B, Hoyer-Hansen G, Rossi G. Differential expression of a truncated form of the urokinase-type plasminogen activator receptor in normal and tumor thyroid cells. Cancer Res. 1998;58:1315
  19. Wohn KD, Kanse SM, Deutsch V, Schmidt T, Eldor A, Preissner KT. The urokinase-receptor (CD87) is expressed in cells of the megakaryoblastic lineage. Thrombosis Haemostasis. 1997;77:540
  20. M’Liss A, Hudson L, McReynolds LM. Urokinase and the urokinase receptor: association with in vitro invasiveness of human bladder cancer cell lines. JNCI. 1997;89:709
  21. Mohanam S, Sawaya R, McCutcheon I, Ali-Osman F, Boyd D, Rao JS. Modulation of in vitro invasion of human glioblastoma cells by urokinase-type plasminogen activator receptor antibody. Cancer Res. 1993;53:4143
  22. Ploug M, Ostergaard S, Gardsvoll H, Kovalski K, Holst-Hansen C, Holm A, et al. Peptide-derived antagonists of the urokinase receptor. Biochemistry. 2001;40:12157
  23. Ippoliti R, Lendaro E, Benedetti PA, Torrisi MR, Belleudi F, Carpani D, et al.  Endocytosis of a chimera between human pro-urokinase and the plant toxin saporin: an unusual internalization mechanism. FASEB J. 2000;14:1335
  24. Rajagopal V, Kreitman RJ. Recombinant toxins that bind to the urokinase receptor are cytotoxic without requiring binding to the a2-macroglobulin receptor. J Biol Chem. 2000;275:7566
  25. Engelholm LH, Nielsen BS, Netzel-Arnett S, Solberg H, Chen XD, Garcia JML, et al.  The urokinase plasminogen activator receptor-associated protein/Endo180 is coexpressed with its interaction partners urokinase plasminogen activator receptor and matrix metalloprotease-13 during osteogenesis. Lab Invest. 2001;81:1403
  26. Vallera DA, Li C., Panoskaltsis-Mortari A, Hall WA, Targeting overexpressed urokinase-type plasminogen activator receptor (uPAR) on human glioblastoma with the diphtheria toxin fusion protein DTAT in nude mice, JNCI, (in press).
  27. Tanabe S, Zeleznik-Le NJ, Kobayashi H, Vignon C, Espinosa R, LeBeau MM, et al. Analysis of the t(6;11)(q27;q23) in leukemia shows a consistent breakpoint in AF6 in three patients and in the ML-2 cell line. Genes Chromosomes Cancer. 1996;15:206
  28. Strout MP, Mrozek K, Heinonen K, Sait SNJ, Shows TB, Aplan PD. ML-1 cell line lacks a germline MLL locus. Genes Chromosomes Cancer. 1996;16:204
  29. Kees UR, Campbell LJ, Ford J, Willoughby MLN, Peroni SE, Ranford PR, et al. New translocation t(2;13)(p12;q34) and rearrangement of the MLL gene in a childhood leukemia cell line. Genes Chromosomes Cancer. 1995;12:201
  30. Gill Super HJ, Martinez-Climent J, Rowley JD. Molecular analysis of the Mono Mac 6 cell line: detection of an MLL-AF9 fusion transcript. Blood. 1995;85:855
  31. Steube KG, Teepe D, Meyer C, Zaborski M, Drexler HG. A model system in haematology and immunology: the human monocytic cell line MONO-MAC-1. Leuk Res. 1997;21:327
  32. Walter R, Schoedon G, Bachli E, Betts DR, Hossle JP, Calandra T, et al. Establishment and characterisation of an arsenic-sensitive monoblastic leukaemia cell line (SigM5). Br J Haematol. 2000;109:396
  33. Odero MD, Zeleznik-Le NJ, Chinwalla V, Rowley JD. Cytogenetic and molecular analysis of the acute monocytic leukemia cell line THP-1 with an MLL-AF9 translocation. Genes Chromosomes Cancer. 2000;29:333
  34. Potter GK, Mohamed AN, Dracopoli NC, Groshen SLB, Shen RN, Moore MAS. Action of 1,25-(OH)2D3 in nude mice bearing transplantable human myelogenous leukemic cell lines. Exp Hematol. 1985;13:722
  35. Ohyashiki K, Ohyashiki JH, Kinniburgh AJ, Rowe J, Miller KB, Raza A, et al.  Transposition of breakpoint cluster region (3’ bcr) in CML cells with variant Philiadelphia translocations. Cancer Genet Cytogenet. 1987;26:105
  36. Volpi EV, Vatcheva R, Labella T, Gan SU. More detailed characterization of some of the HL60 karyotypic features by fluorescence in situ hybridization. Cancer Genet Cytogenet. 1996;87:103
  37. Jiang JD, Wang Y, Janish CA, Holland JF, Bekesi JG. 3-bromoacetylamino benzyolurea (3-BAABU), a new antimicrotubule cancericidal agent applied in cytogenetic analysis in hematology. Biomed Pharmacother. 1998;52:270
  38. Kiser M, McCubrey JA, Steelman LS, Shelton JG, Ramage J, Alexander RL, et al.  Oncogene-dependent engraftment of human myeloid leukemia cells in immunosuppressed mice. Leukemia. 2001;15:814
  39. Weiss A, Wiskocil RL, Stobo JD. The role of T3 surface molecules in the activation of human T cells: a two-stimulus requirement for IL-2 production reflects events occurring at a pre-translational level. J Immunol. 1984;133:123
  40. Yoshida MC, Kodama Y. Karyological characterization of a human lymphoblastoid cell line resistant to 6-thioguanine. Hum Genet. 1977;35:201
  41. Shou Y, Martelli ML, Gabrea A, Qi Y, Brents LA, Roschke A, et al.  Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proc Natl Acad Sci U.S.A. 2000;97:228
  42. Falnes PO, Sandvig K. Penetration of protein toxins into cells. Curr Opin Cell Biol. 2000;12:407
  43. Nykjaer A, Christensen EI, Vorum H, Hager H, Petersen CM, Roigaard H, et al.  Mannose 6-phosphate/insulin-like growth factor-II receptor targets the urokinase receptor to lysosomes via a novel binding interaction. J Cell Biol. 1998;141:815
  44. Cavallaro U, del Vecchio A, Lappi DA, Soria MR. A conjugate between human urokinase and saporin, a type-1 ribosome-inactivating protein, is selectively cytotoxic to urokinase receptor-expressing cells. J Biol Chem. 1993;268:23186
  45. Fabbrini MS, Carpani D, Soria MR, Ceriotti A. Cytosolic immunization allows the expression of preATF-saporin chimeric toxin in eukaryotic cells. FASEB J. 2000;14:391
  46. Drexler HG, Zaborski M, Quentmeier H. Cytokine response profiles of human myeloid factor-dependent leukemia cell lines. Leukemia. 1997;11:701
  47. Chen P, Chiu C, Chiou T, Maeda S, Chiang H, Tzeng C, et al. Establishment and characterization of a human monocytoid leukemia cellline CTV-1. Gann. 1984;75:660
  48. Wang C, Curtis JE, Minden MD, McCulloch EA. Expression of a retinoid acid receptor gene in myeloid leukemia cells. Leukemia. 1989;3:264
  49. Koeffler HP. Induction of differentiation of human acute myelogenous leukemia cells: therapeutic implications. Blood. 1983;62:709
  50. Asou H, Tashiro S, Hamamoto K, Otsuji A, Kita K, Kamada N. Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation. Blood. 1991;77:2031
  51. Minowada, J., Immunology of leukemic cells. In: Gunz, F, Henderson, E, editors. Leukemia. Orlando (FL, USA): Grune & Stratton, 1982. p. 119.

PII: S0145-2126(02)00077-2

Leukemia Research
Volume 27, Issue 1 , Pages 79-84 , January 2003

Article Tools

* Image Usage & Resolution